August 13, 2025

Frank Karbe
Chief Financial Officer
Cidara Therapeutics, Inc.
6310 Nancy Ridge Dr.
Suite 101
San Diego, CA 92121

        Re: Cidara Therapeutics, Inc.
            Form 10-K for the period ended December 31, 2024
            Filed March 6, 2025
            File No. 001-36912
Dear Frank Karbe:

       We have reviewed your filing and have the following comment(s).

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe a
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this letter, we may have additional
comments.

Annual Report on Form 10-K
Cloudbreak Oncology Pipeline, page 9

1.     Please revise the pipeline table in future filings both here and on page
64 to add an
       additional column for Phase 3 of clinical testing and further revise the
table so that
       there are no more than two preclinical columns. We also note that you
have included
       rows in your pipeline table for the PD-1/CD73 and CCR5 programs, which
are
       minimally discussed in the annual report and for which you have yet to
identify a
       product candidate. In future filings, as applicable, please revise to
remove these
       programs from the table. Alternatively, please provide us with an
analysis
       explaining why each of these programs should be highlighted in your
pipeline table.
 August 13, 2025
Page 2

Janssen License Agreement, page 13

2.     Please expand your disclosure of the license and technology transfer
agreement with
       Janssen in future filings to describe the termination provisions.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Please contact Chris Edwards at 202-551-6761 or Joe McCann at
202-551-6262 if you
have questions regarding the comments or with any other questions.



                                                          Sincerely,

                                                          Division of
Corporation Finance
                                                          Office of Life
Sciences